Edition:
United Kingdom

People: Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

18.52USD
18 Apr 2019
Change (% chg)

-- (--)
Prev Close
$18.52
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
205,595
52-wk High
$27.00
52-wk Low
$10.30

McCue, Justin 

Dr. Justin McCue Ph.D. is Vice President of Chemistry, Manufacturing and Controls of the company. As vice president of CMC, Dr. McCue oversees for Omeros all development, manufacturing, and supply of both biological and small-molecule drugs. Dr. McCue joins Omeros from Celgene where he headed the development of CAR T-cell and T-cell receptor (TCR) therapy manufacturing processes. Prior to Celgene, he led Biogen's CMC activities for the multi-billion-dollar drugs AVONEX ® and PLEGRIDY ® , approved for the treatment of multiple sclerosis in more than 90 countries. He began his career in the biopharmaceutical division at Millipore. Dr. McCue earned his Ph.D. and completed a post-doctoral fellowship in chemical engineering at Massachusetts Institute of Technology (M.I.T.) after receiving a degree in chemical engineering at University of California at Berkeley.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Gregory Demopulos

4,535,280

Michael Jacobsen

1,016,330

Marcia Kelbon

1,219,050

Daniel Kirby

--

Justin McCue

--

Thomas Cable

106,050
As Of  31 Dec 2017